Kidney Cancer

Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading

Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading

By

A review article examines the challenges in pathologic staging and grade reporting for patients with renal cell carcinoma.

Karyopherin a2 May Be Prognostic Indicator in Renal Cell Carcinoma

Karyopherin a2 May Be Prognostic Indicator in Renal Cell Carcinoma

By

Researchers theorize that KPNA2 expression could be used in the future to stratify risk groups among patients with renal cell carcinoma (RCC).

The Changing Treatment Landscape for Advanced Renal Cell Carcinoma

The Changing Treatment Landscape for Advanced Renal Cell Carcinoma

By

Interferon or high-dose interleukin-2 were the only available options for the treatment of metastatic RCC until 2005.

VEGF-TKI Adjuvant Trial Results in Renal Cell Carcinoma Highlight Controversy in Treatment Strategy

VEGF-TKI Adjuvant Trial Results in Renal Cell Carcinoma Highlight Controversy in Treatment Strategy

By

Insights into controversial results of trials evaluating adjuvant vascular endothelial growth factor tyrosine kinase inhibitors in high-risk renal cell carcinoma.

Microwave Ablation for Early-Stage Renal Tumors

Microwave Ablation for Early-Stage Renal Tumors

By

Image-guided microwave ablation of early-stage renal tumors shows promise but a new retrospective study from the Mayo Clinic found some cases of major bleeding.

High Distress in Patients With Renal Cell Carcinoma, Call for Better Psychosocial Screening

High Distress in Patients With Renal Cell Carcinoma, Call for Better Psychosocial Screening

By

A high prevalence of patients with renal cell carcinoma reported distress, highlighting the need for better psychosocial screening of patients.

Cabozantinib Effective Regardless of PD-L1 Expression in RCC

Cabozantinib Effective Regardless of PD-L1 Expression in RCC

By

PD-L1 tumor expression was found not to be a predictive biomarker for cabozantinib efficacy in mRCC.

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma

By

Long-term oncologic outcomes of patients with sporadic RCC who underwent robotic tumor enucleation suggest the procedure is safe.

Drug Targeting ENPP3 Is Active in Heavily Pretreated, Advanced Metastatic RCC

Drug Targeting ENPP3 Is Active in Heavily Pretreated, Advanced Metastatic RCC

By

An antibody-drug conjugate targeting ectonucleotide pyrophosphatase/phosphodiesterase 3 conjugated to monomethyl auristatin F had some antitumor activity in patients with advanced, metastatic renal cell carcinoma.

The Identification of a Potential Early Plasma Biomarker for Kidney Cancer

The Identification of a Potential Early Plasma Biomarker for Kidney Cancer

By

Researchers found that doubling in KIM-1 plasma concentrations was associated with an increased risk of developing RCC and poorer survival.

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

By

When sunitinib was given as an adjuvant therapy in renal cell carcinoma, patients reported worse symptoms and lower health-related quality of life scores.

Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC

Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC

By

Stereotactic body radiation therapy (SBRT) may be a safe and effective therapeutic option that couold provide localized control.

Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes

Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes

By

The impact of switching to or continuing treatment with systemic therapy post-stereotactic radiosurgery in renal cell carcinoma requires further study.

Robotic Partial Nephrectomy Compared With Open, Laparoscopic Partial Nephrectomy

Robotic Partial Nephrectomy Compared With Open, Laparoscopic Partial Nephrectomy

By

A meta-analysis compared outcomes between the use of partial nephrectomy using a robotic surgical approach and open or laparoscopic partial nephrectomy.

Nonsurgical treatment of small tumor renal cancer may be as effective as radical nephrectomy but with fewer complications

Renal stage carcinoma (RCC) has relatively low mortality rates with respect to cancer diagnoses, as the disease tends to be slow growing.

Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma

Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma

By

Circulating blood biomarkers related to angiogenesis may help clinicians predict who will have a robust response to sunitinib.

A High Level of Circulating Vitamin D Protein Is Associated With a Decreased Risk of Kidney Cancer

A High Level of Circulating Vitamin D Protein Is Associated With a Decreased Risk of Kidney Cancer

By

Research focused on renal cell carcinoma appears to confirm the potential etiologic role of vitamin D binding protein in cancer.

Lower Costs of Pazopanib for Advanced RCC May Influence Drug Choice

Lower Costs of Pazopanib for Advanced RCC May Influence Drug Choice

By

Any new study of pazopanib or sunitinib must be placed in perspective of the changing treatment landscape and the market entrance of new immunotherapies.

Certain Renal Cancer Subtypes Linked to Obesity

Certain Renal Cancer Subtypes Linked to Obesity

By

Obesity is associated with an increased likelihood of clear cell and possibly chromophobe renal cell carcinoma.

High Body Mass Index May Predict Survival Outcomes in Renal Cell Carcinoma

High Body Mass Index May Predict Survival Outcomes in Renal Cell Carcinoma

By

The association between obesity, age, and renal cell carcinoma prognosis requires additional investigation.

Heading Toward Personalized Management of Advanced Kidney Cancer

Heading Toward Personalized Management of Advanced Kidney Cancer

By

The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

By

Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.

Carmena Trial: Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone

Carmena Trial: Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the findings at the ASCO 2018 meeting.

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

By

The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

By

Researchers assigned 38 patients with metastatic renal cell carcinoma to receive pegilodecakin plus nivolumab or pembrolizumab.

Diabetes Ups Kidney Cancer Risk in Women

Diabetes Ups Kidney Cancer Risk in Women

By

Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.

Renal Cell Carcinoma:  How Biomarkers Could Affect Drug Development

Renal Cell Carcinoma: How Biomarkers Could Affect Drug Development

By

An example of where biomarkers may help to select the best medication for a patient and also assist in drug development is the tyrosine kinase inhibitor (TKI) dovitinib for renal cell carcinoma (RCC).

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

By

The phase 3 METEOR study previously demonstrated that cabozantinib significantly improved survival outcomes among patients with relapsed renal cell carcinoma.

No Single Gene Seems to Drive Renal Cell Carcinoma Metastasis

No Single Gene Seems to Drive Renal Cell Carcinoma Metastasis

By

Recent research indicates that there were no significant differences in the genomic landscape of clear cell RCC primary tumors and metastases, or between the different sites of metastases.

Does Sunitinib Have A Future in Renal Cell Carcinoma Treatment?

Does Sunitinib Have A Future in Renal Cell Carcinoma Treatment?

By

Immunotherapy may supplant sunitinib in RCC, except for in patients who cannot tolerate checkpoint inhibition.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs